You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The tests will run on Bosch's automated Vivalytic platform, with BioGX developing, manufacturing, and supplying reagents for the cartridges.
The firm expects to launch a 510(k)-cleared version of its Bladder EpiCheck recurrence assay early next year followed by an RUO early-stage lung cancer assay.
Swiss firm DKSH will market and sell Ubiquitome's Liberty16 PCR-based platform in Australia, New Zealand, and other countries in the region.
Children's Hospital Los Angeles used a SARS-CoV-2 sequencing panel to determine if patients had become infected from the same source as healthcare workers.
The company will use the funds to increase manufacturing, supply, and testing capacity for the SARS-CoV-2 test it launched in March.
The German company's real-time PCR test is designed to detect SARS-CoV-2 genes E and RdRP in respiratory samples.
The UK Department of Health and Social Care has already ordered 10,000 RNA test cartridges from the company, which expects to obtain a CE-IVD mark for its test within weeks.
Fluidigm's Biomark HD microfluidic platform will enable more than 180,000 real-time PCR tests to be run over the next 90 days to potentially support COVID-19 screening.
The researchers said their assay can be run in 30 to 45 minutes, with 95 percent positive predictive agreement and 100 percent negative predictive agreement.
The company's approach relies on an initial point-of-care lateral flow assay followed by a confirmatory real-time PCR analysis run in its laboratories.